Literature DB >> 16225478

Review article: role of oxidative stress in the progression of non-alcoholic steatosis.

E Albano1, E Mottaran, G Occhino, E Reale, M Vidali.   

Abstract

The mechanisms responsible for the progression of nonalcoholic fatty liver disease (NAFLD) to more severe liver injury are still poorly understood. Data from animal models suggest that oxidative stress contributes to steatohepatitis and an increase of lipid peroxidation has been documented in human NAFLD. By measuring the titers of circulating antibodies against lipid peroxidation products as markers of oxidative stress we have observed that NAFLD patients have titers of these antibodies significantly higher than in controls. Moreover, the titers of lipid peroxidation-related antibodies are associated with a 3-fold increase in the risk of developing advanced fibrosis/cirrhosis. Although the mechanisms causing oxidative stress in NAFLD have not been elucidated, these results support the involvement of lipid peroxidation in the processes leading to liver fibrosis associated with NAFLD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16225478     DOI: 10.1111/j.1365-2036.2005.02601.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  42 in total

1.  Current and novel therapies for the treatment of nonalcoholic steatohepatitis.

Authors:  David van der Poorten; Jacob George
Journal:  Hepatol Int       Date:  2007-07-26       Impact factor: 6.047

2.  Hepatocellular ballooning in NASH.

Authors:  Stephen Caldwell; Yoshihiro Ikura; Daniela Dias; Kosuke Isomoto; Akito Yabu; Christopher Moskaluk; Patcharin Pramoonjago; Winsor Simmons; Harriet Scruggs; Nicholas Rosenbaum; Timothy Wilkinson; Patsy Toms; Curtis K Argo; Abdullah M S Al-Osaimi; Jan A Redick
Journal:  J Hepatol       Date:  2010-06-25       Impact factor: 25.083

Review 3.  p62/SQSTM1-Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer.

Authors:  Koji Taniguchi; Shinichiro Yamachika; Feng He; Michael Karin
Journal:  FEBS Lett       Date:  2016-08-06       Impact factor: 4.124

4.  Permethrin and ivermectin modulate lipid metabolism in steatosis-induced HepG2 hepatocyte.

Authors:  Jason S Yang; Weipeng Qi; Renalison Farias-Pereira; Stephanie Choi; John M Clark; Daeyoung Kim; Yeonhwa Park
Journal:  Food Chem Toxicol       Date:  2019-02-06       Impact factor: 6.023

5.  High Sucrose Intake Ameliorates the Accumulation of Hepatic Triacylglycerol Promoted by Restraint Stress in Young Rats.

Authors:  Adriana Corona-Pérez; Mauricio Díaz-Muñoz; Ida Soto Rodríguez; Estela Cuevas; Margarita Martínez-Gómez; Francisco Castelán; Jorge Rodríguez-Antolín; Leticia Nicolás-Toledo
Journal:  Lipids       Date:  2015-09-23       Impact factor: 1.880

Review 6.  Vitamin D: a new player in non-alcoholic fatty liver disease?

Authors:  Myrto Eliades; Elias Spyrou
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

7.  Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease.

Authors:  Shikha S Sundaram; Ronald J Sokol; Kelley E Capocelli; Zhaoxing Pan; Jillian S Sullivan; Kristen Robbins; Ann C Halbower
Journal:  J Pediatr       Date:  2013-12-07       Impact factor: 4.406

Review 8.  A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease.

Authors:  P Riley; J O'Donohue; M Crook
Journal:  J Clin Pathol       Date:  2007-05-04       Impact factor: 3.411

Review 9.  Hypertension and hepatic steatosis.

Authors:  Matthew J Brookes; Tariq H Iqbal; Brian T Cooper
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

10.  Chemical imaging on liver steatosis using synchrotron infrared and ToF-SIMS microspectroscopies.

Authors:  François Le Naour; Marie-Pierre Bralet; Delphine Debois; Christophe Sandt; Catherine Guettier; Paul Dumas; Alain Brunelle; Olivier Laprévote
Journal:  PLoS One       Date:  2009-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.